首頁 › 非小細胞肺癌 › 南卡羅來納州 › Charleston
Charleston, SC 的 非小細胞肺癌 臨床試驗
16 項針對 非小細胞肺癌 的研究正在 Charleston（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Medical University of South Carolina /ID# 273272, Charleston
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Bon Secours Saint Francis Hospital, Charleston
- Medical University of South Carolina, Charleston
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
招募中3 期
- Medical University of South Carolina-Hollings Cancer Center ( Site 0045), Charleston
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Medical University of South Carolina, Charleston
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
招募中3 期
- Medical University of South Carolina, Charleston
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
招募中1/2 期
- MUSC Hollings Cancer Center, Charleston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
招募中3 期
- Medical University of South Carolina, Charleston
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
招募中3 期
- Medical University of South Carolina, Charleston
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
招募中2 期
- Ralph H Johnson VA Medical Center, Charleston
- Medical University of South Carolina, Charleston
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
招募中2 期
- USA03-0, Charleston
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- Ralph H Johnson VA Medical Center, Charleston
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
招募中2/3 期
- Medical University of South Carolina, Charleston
Phase 2 Study of Fingolimod in Lung Cancers
招募中2 期
- Hollings Cancer Center at Medical University of South Carolina, Charleston
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
招募中觀察性研究
- Medical University of South Carolina, Charleston
GEMINI-NSCLC: NSCLC Biomarker Study
招募中觀察性研究
- The Medical University of South Carolina, Charleston
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
招募中1/2 期
- Research Site 123, Charleston
其他城市的 非小細胞肺癌 試驗
- Houston, TX145 項研究
- New York City, NY121 項研究
- Arlington, VA104 項研究
- Nashville, TN97 項研究
- Boston, MA90 項研究
- Los Angeles, CA87 項研究
- St. Louis, MO73 項研究
- Chicago, IL61 項研究
- Baltimore, MD60 項研究
- San Antonio, TX59 項研究
- Columbus, OH57 項研究
- Washington, DC55 項研究
Charleston 的其他研究
- 憂鬱症19 項研究
- 中風18 項研究
- 心臟衰竭18 項研究
- 創傷後壓力症候群16 項研究
- 心血管疾病15 項研究
- 前列腺癌15 項研究
- 癌症（所有類型）14 項研究
- 頭頸部鱗狀細胞癌14 項研究
- 帕金森氏症13 項研究
- 間質性肺病13 項研究
- 乳癌12 項研究
- 肺癌11 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。